Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)-Reference-Cited by-同舟云学术

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Published:2017-04-21 Issue:2 Volume:24 Page:199-205
ISSN:1219-4956
Container-title:Pathology & Oncology Research
language:en
Short-container-title:Pathol. Oncol. Res.

Author:

Schneider Tamás,Rosta András,Losonczy Hajna,Radványi Gáspár,Ujj György,Egyed Miklós,Illés Árpád,Jakucs János,Szerafin László,Gasztonyi Zoltán,Masszi Tamás,Iványi János,Demeter Judit,Dombi Péter,Tóth Antal,Borbényi Zita

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1007/s12253-017-0234-2/fulltext.html

Reference28 articles.

1. Greenhalgh J, Bagust A, Boland A et al (2013) Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: a NICE single technology appraisal. PharmacoEconomics 31(5):403–413

2. Gallagher CJ, Gregory WM, Jones AE et al (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4(10):1470–1480

3. Piro LD, White CA, Grillo-López AJ et al (1990) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 10:655–661

4. Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450–454

5. Reff ME, Carner K, Chambers KS (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional evaluation of various ICAM3 transcript variants in diffuse large B-Cell lymphoma;Leukemia & Lymphoma;2022-07-18

2. Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study;Blood Advances;2021-09-03

3. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study;Haematologica;2021-06-17

4. Fenntartó kezelési módok felnőttkori rosszindulatú hematológiai betegségekben;Orvosi Hetilap;2020-09

5. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA;Journal of Comparative Effectiveness Research;2019-04